Paris-Sud University, Faculty of Pharmacy, EA 401, "Groupe Matériaux et Santé", Paris, France.
Biomater Sci. 2018 Jul 24;6(8):2025-2053. doi: 10.1039/c8bm00518d.
Biomaterials play an increasing role in modern health care systems. Biocompatibility poses a significant challenge for manufacturers of medical devices and contemporary intelligent drug delivery technologies from materials development to market approval. Despite a highly regulated environment, biocompatibility evaluation of biomaterials for medical devices is a complex task related to various factors that include mainly chemical nature and physical properties of the material, the contact tissue and duration of contact. Although international standards, such as ISO 10993-1, are generally employed to prove regulatory compliance needed for market clearance or for initiating clinical investigations, they may not offer sufficient guidance, or risk-management perspective when it comes to choosing materials or appropriate in vitro biocompatibility screening methods when developing medical devices. The global normative approach towards the biocompatibility evaluation of medical devices is presented in this review, with a focus on in vitro studies. Indeed, a risk-management approach towards the judicial choice of in vitro tests throughout the development and production of medical devices and drug delivery systems will facilitate rapid regulatory approval, avoid unnecessary animal studies, and ultimately reduce risks for patients. A detailed overview towards the construction of a comprehensive biological evaluation plan is described herein, with a focus on polymer-based materials used in medical applications. Polymeric materials offer a broad spectrum of applications in the manufacturing of medical devices. They are extensively employed within both conventional and innovative drug delivery systems with superior attributes supporting robust, extended use capacity, capable of meeting specific requirement such as adhesion, drug release, and more. Various methods of biocompatibility assessment are detailed within, with an emphasis on scientific analysis. This review may be of interest to those involved in the design, manufacturing and in vitro testing of medical devices and innovative drug delivery technologies, specifically with respect to a risk-management approach towards the biocompatibility assessment of polymer-based devices.
生物材料在现代医疗保健系统中发挥着越来越重要的作用。生物相容性对医疗器械制造商和当代智能药物输送技术构成了重大挑战,从材料开发到市场批准都面临着这一挑战。尽管环境受到高度监管,但医疗器械生物材料的生物相容性评估是一项复杂的任务,涉及到许多因素,主要包括材料的化学性质和物理性质、接触组织和接触时间。尽管国际标准,如 ISO 10993-1,通常用于证明医疗器械市场准入或启动临床研究所需的监管合规性,但在选择材料或适当的体外生物相容性筛选方法时,它们可能无法提供足够的指导或风险管理视角。本文介绍了医疗器械生物相容性评估的全球规范方法,重点介绍了体外研究。事实上,在医疗器械和药物输送系统的开发和生产过程中,采用风险管理方法来司法选择体外试验,将有助于快速获得监管批准,避免不必要的动物研究,并最终降低患者的风险。本文详细介绍了构建全面生物评估计划的方法,重点是用于医疗应用的聚合物材料。聚合物材料在医疗器械制造中具有广泛的应用。它们广泛应用于传统和创新的药物输送系统中,具有优越的属性,支持强大、扩展的使用能力,能够满足特定的要求,如粘附、药物释放等。本文详细介绍了各种生物相容性评估方法,重点是科学分析。对于参与医疗器械和创新药物输送技术的设计、制造和体外测试的人员来说,本文可能具有参考意义,特别是在聚合物基器械的生物相容性评估方面,采用风险管理方法。